文章摘要
朱烟林,康 敏,彭时成,杨 倩,文 婷.复方谷氨酰胺联合双歧杆菌三联活菌胶囊对腹泻型肠易激综合征患者肠黏膜屏障功能、胃肠激素和血清5-HT、SPY水平的影响[J].,2022,(2):352-355
复方谷氨酰胺联合双歧杆菌三联活菌胶囊对腹泻型肠易激综合征患者肠黏膜屏障功能、胃肠激素和血清5-HT、SPY水平的影响
Effects of Compound Glutamine Combined with Bifidobacterium Triple Viable Capsule on Intestinal Mucosal Barrier Function, Gastrointestinal Hormone and Serum 5-HT and SPY Levels in Patients with Diarrhea Irritable Bowel Syndrome
投稿时间:2021-06-19  修订日期:2021-07-14
DOI:10.13241/j.cnki.pmb.2022.02.030
中文关键词: 复方谷氨酰胺  双歧杆菌三联活菌  腹泻型肠易激综合征  肠黏膜屏障功能  胃肠激素  5-羟色胺  神经肽Y
英文关键词: Compound glutamine  Bifidobacterium triple viable capsule  Diarrhea irritable bowel syndrome  Intestinal mucosal barrier function  Gastrointestinal hormone
基金项目:四川省卫计委科研资助项目(17PJ049)
作者单位E-mail
朱烟林 西南医科大学附属医院消化内科 四川 泸州 646000 yanlinzhu123456@163.com 
康 敏 西南医科大学附属医院消化内科 四川 泸州 646000  
彭时成 西南医科大学附属医院消化内科 四川 泸州 646000  
杨 倩 西南医科大学附属医院消化内科 四川 泸州 646000  
文 婷 西南医科大学附属医院消化内科 四川 泸州 646000  
摘要点击次数: 618
全文下载次数: 273
中文摘要:
      摘要 目的:探究复方谷氨酰胺联合双歧杆菌三联活菌胶囊对腹泻型肠易激综合征(IBS-D)患者肠黏膜屏障功能、胃肠激素和血清5-羟色胺(5-HT)、神经肽Y(SPY)水平的影响。方法:选取2019年3月-2021年3月我院收治的IBS-D患者104例,根据随机数字表法将其分为A组、B组各52例。A组给予复方谷氨酰胺治疗,B组给予复方谷氨酰胺联合双歧杆菌三联活菌胶囊治疗,两组均治疗4周。检测并比较两组胃肠激素和血清5-HT、SPY水平,肠黏膜屏障功能指标及治疗疗效。记录治疗期间不良反应发生情况。结果:B组治疗后总有效率较A组高(P<0.05)。治疗后两组5-HT水平下降,SPY水平上升,且与A组相比,B组治疗后5-HT水平较低,SPY水平较高(P<0.05);治疗后两组内毒素、D-乳酸、二胺氧化酶(DAO)水平均下降,且与A组相比,B组治疗后内毒素、D-乳酸、DAO水平较低(P<0.05);治疗后B组血管活性肠肽(VIP)、生长抑素(SS)水平低于A组(P<0.05)。治疗期间两组均未发生不良反应。结论:IBS-D患者经复方谷氨酰胺联合双歧杆菌三联活菌胶囊治疗疗效显著,可改善患者肠黏膜屏障功能、胃肠激素和血清5-HT、SPY水平,且无明显不良反应,安全性较高,值得临床联合使用。
英文摘要:
      ABSTRACT Objective: To explore the effects of compound glutamine combined with bifidobacterium triple viable capsule on intestinal mucosal barrier function, gastrointestinal hormone, serum serotonin (5-HT) and neuropeptide Y (SPY) in patients with diarrhea irritable bowel syndrome (IBS-D). Methods: 104 patients with IBS-D treated in our hospital from March 2019 to March 2021 were selected. According to the random number table method, they were divided into group A and group B, with 52 cases in each group. Group A was treated with compound glutamine and group B was treated with compound glutamine combined with bifidobacterium triple viable capsule. Both groups were treated for 4 weeks. Gastrointestinal hormones, serum 5-HT and SPY levels, intestinal mucosal barrier function indexes and therapeutic effects were detected and compared between the two groups. Adverse reactions during treatment were recorded. Results: The total effective rate in group B was higher than that in group A(P<0.05). After treatment, the level of 5-HT decreased and the level of SPY increased in the two groups. Compared with group A, the level of 5-HT in group B was lower and the level of SPY was higher (P<0.05). The levels of endotoxin, D-lactic acid and diamine oxidase (DAO) in the two groups decreased after treatment, and the levels of endotoxin, D-lactic acid and DAO in group B were lower than those in group A(P<0.05). After treatment, the levels of vasoactive intestinal peptide (VIP) and somatostatin (SS) in group B were lower than those in group A(P<0.05). There were no adverse reactions in the two groups during treatment. Conclusion: IBS-D patients treated with compound glutamine combined with bifidobacterium triple viable capsule have significant curative effect, which can improve the intestinal mucosal barrier function, gastrointestinal hormone and serum 5-HT and SPY levels, with no obvious adverse reactions and high safety. It is worthy of clinical combined use.
查看全文   查看/发表评论  下载PDF阅读器
关闭